Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.